STAMATIS.AI
STAMATIS.AI
STAMATIS.AI is building the Locus Platform — an agentic AI engine designed to replace the fragmented landscape of narrow, single-indication imaging tools with one unified, patent-protected architecture.
Radiology is fragmenting under workload pressure while AI arrives in narrow, uncoordinated point solutions. Hospitals cannot integrate twenty separate vendor contracts to cover enterprise imaging — and single-indication tools miss the cross-organ patterns that matter clinically.
Locus is different. A single patent-protected core engine with organ-specific modules for brain, heart, lungs, liver, and pancreas. One architecture. One integration. One validation framework.
The first product — Locus.brain for glioma detection on MRI — enters FDA 510(k) validation on a defined regulatory path. The platform expands module-by-module, de-risked by each clearance.
A defensible IP position built deliberately over two years — allowable US claims, a divisional for breadth, and international protection via PCT. One hundred percent owned by the Company. No university technology transfer office. No royalty. No gatekeeper on commercial decisions.
Application 19/200,539 — claims found allowable at USPTO. Formal issuance expected late 2026.
Additional claim scope separated from the parent to maximize protection breadth across platform elements.
International filing rights preserved across PCT member states. National phase strategy under founder control.
Fully owned by Cornerstone Eagle LLC. No university license. No TTO approval required on commercial decisions.
Each module reuses the shared core architecture, meaning every successive clearance is faster, less expensive, and less risky than the one before it.
The lead indication — glioma on brain MRI — enters 510(k) validation on a defined predicate path. Cardiac and pulmonary modules follow once the core platform is cleared.
Glioma detection & characterization · MRI
Cardiac structure & function · MRI/CT
Pulmonary disease · CT
Hepatic disease · MRI/CT
Pancreatic disease · MRI/CT
Every number below is audited, verifiable, and reflects real commitment to the platform. No pre-revenue inflation. No placeholder claims.
Founder capital, technical depth, and clinical leadership — aligned on a single thesis about where diagnostic imaging goes next.
Inventor on US 19/200,539. Founder-funded the platform through patent allowance. Leads strategy, fundraising, and commercial partnerships.
Leads platform architecture, model development, and engineering execution. Personal capital contribution to platform build.
Double board-certified interventional pain management. Founder & CEO of a 13-location North Texas physician network.
STAMATIS.AI welcomes inquiries from accredited investors with experience in healthcare AI, medical devices, and regulated software. A full briefing, clinical roadmap, and data room are available to qualified parties following a mutual NDA.
This page is informational and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities will be made only to accredited investors under exempt private placement rules, through definitive offering documents furnished directly to qualified recipients. Patent applications referenced are pending and subject to USPTO examination. The Locus Platform is not FDA-cleared for commercial use.